1. FDA Requires Boxed Warning and Risk Mitigation Strategy for Metoclopramide-containing Drugs., [ http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm149533.htm ]
2. Metoclopramide: Strong Warnings on Risk of Abnormal Muscle Movements., [ http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2011/13627a-eng.php ]
3. European Medicines Agency Recommends Changes to the Use of Metoclopramide. 2013, European Medicines Agency, London
4. European Medicines Agency: Assessment Report for Metoclopramide-containing Medicines., [ http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Metoclopramide-containing_medicines/human_referral_000349.jsp&mid=WC0b01ac05805c516f ]
5. Shaffer D, Butterfield M, Pamer C, Mackey AC: Tardive dyskinesia risks and metoclopramide use before and after U.S. market withdrawal of cisapride. J Am Pharm Assoc. 2004, 44: 661-665. 10.1331/1544345042467191.